Media stories about ABIOMED (NASDAQ:ABMD) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ABIOMED earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned media stories about the medical equipment provider an impact score of 45.2958252610604 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the media stories that may have effected Accern Sentiment’s rankings:
- De Burlo Group Inc Buys Applied Materials Inc, American Tower Corp, Netflix Inc, Sells C.R. … (nasdaq.com)
- ABIOMED, Inc. (ABMD) Stock Rating Reaffirmed by SunTrust Banks, Inc. (americanbankingnews.com)
- ABIOMED, Inc. (ABMD) Director Sells $1,139,665.12 in Stock (americanbankingnews.com)
- Insider Selling: ABIOMED, Inc. (ABMD) VP Sells 10,000 Shares of Stock (americanbankingnews.com)
- Innovative stocks: ABIOMED, Inc., (NASDAQ: ABMD), Sumitomo Mitsui Financial Group, Inc., (NYSE: SMFG), Eldorado … – Stocks In The News (press release) (tradingnewsnow.com)
A number of brokerages have weighed in on ABMD. Jefferies Group LLC boosted their price target on ABIOMED from $175.00 to $208.00 and gave the stock a “buy” rating in a research report on Friday, September 29th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $160.00 price target on shares of ABIOMED in a research report on Tuesday, August 29th. Zacks Investment Research raised ABIOMED from a “hold” rating to a “strong-buy” rating and set a $163.00 price target for the company in a research report on Thursday, July 13th. BidaskClub raised ABIOMED from a “hold” rating to a “buy” rating in a research report on Thursday, August 10th. Finally, BTIG Research reaffirmed a “hold” rating on shares of ABIOMED in a research report on Sunday, October 29th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $183.25.
ABIOMED (NASDAQ ABMD) opened at $194.90 on Monday. The company has a quick ratio of 5.20, a current ratio of 5.84 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $8,617.73, a price-to-earnings ratio of 124.94, a PEG ratio of 2.60 and a beta of 0.23.
ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.16. ABIOMED had a return on equity of 13.89% and a net margin of 18.27%. The business had revenue of $132.80 million during the quarter, compared to analysts’ expectations of $131.18 million. During the same quarter in the previous year, the firm earned $0.20 EPS. The firm’s revenue was up 28.9% compared to the same quarter last year. equities research analysts anticipate that ABIOMED will post 2.38 earnings per share for the current year.
In related news, VP Andrew J. Greenfield sold 11,282 shares of the business’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $169.32, for a total transaction of $1,910,268.24. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Eric A. Md Rose sold 982 shares of the business’s stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $145.17, for a total value of $142,556.94. Following the transaction, the director now owns 13,634 shares in the company, valued at $1,979,247.78. The disclosure for this sale can be found here. Insiders have sold a total of 61,646 shares of company stock valued at $10,003,780 in the last three months. 7.00% of the stock is owned by insiders.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.com-unik.info/2017/11/06/abiomed-abmd-earns-news-sentiment-rating-of-0-15.html.
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
What are top analysts saying about ABIOMED Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ABIOMED Inc. and related companies.